Entasis Therapeutics Stock Forecast, Price & News

-0.09 (-3.81 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume71,700 shs
Average Volume354,104 shs
Market Capitalization$84.69 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Entasis Therapeutics logo

About Entasis Therapeutics

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.06 out of 5 stars

Medical Sector

509th out of 2,220 stocks

Pharmaceutical Preparations Industry

250th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

Is Entasis Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Entasis Therapeutics stock.
View analyst ratings for Entasis Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Entasis Therapeutics?

Wall Street analysts have given Entasis Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Entasis Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 448,600 shares, an increase of 37.1% from the June 15th total of 327,300 shares. Based on an average trading volume of 395,800 shares, the days-to-cover ratio is currently 1.1 days. Approximately 8.7% of the shares of the stock are sold short.
View Entasis Therapeutics' Short Interest

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Entasis Therapeutics

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) released its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.29) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.06.
View Entasis Therapeutics' earnings history

How has Entasis Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ETTX stock has decreased by 45.0% and is now trading at $2.27.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ETTX?

3 Wall Street analysts have issued 12-month target prices for Entasis Therapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Entasis Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 120.3% from the stock's current price.
View analysts' price targets for Entasis Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Dr. Manoussos Perros, Pres, CEO & Director (Age 53, Pay $934.85k)
  • Dr. John Patrick Mueller Ph.D., Chief Devel. Officer (Age 61, Pay $584.55k)
  • Dr. David Altarac, Chief Medical Officer (Age 60, Pay $598.29k)
  • Dr. Michael J. Gutch, CFO, Chief Bus. Officer & Sec. (Age 55)
  • Dr. Ruben Tommasi, Chief Scientific Officer (Age 55)
  • Ms. Elizabeth M. Keiley, Gen. Counsel (Age 55)
  • Ms. Colleen Tucker, Head of HR
  • Dr. Matthew Ronsheim Ph.D., Chief Pharmaceutical Sciences & Manufacturing Officer (Age 49)

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an IPO on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.27.

How much money does Entasis Therapeutics make?

Entasis Therapeutics has a market capitalization of $84.69 million and generates $7 million in revenue each year. The company earns $-50,500,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Entasis Therapeutics have?

Entasis Therapeutics employs 47 workers across the globe.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is

Where are Entasis Therapeutics' headquarters?

Entasis Therapeutics is headquartered at 35 GATEHOUSE DRIVE, WALTHAM MA, 02451.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at (781) 810-0120 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.